The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
Open accessAbstract
BACKGROUND: Previous studies have suggested that the use of nonsteroidal antiinflammatory drugs (NSAIDs) may help to prevent Alzheimer's disease. The results, however, are inconsistent. METHODS: We studied the association between the use of NSAIDs and Alzheimer's disease and vascular dementia in a prospective, population-based cohort study of 6989 subjects 55 years of age or older who were free of dementia at base line, in 1991. To detect new cases of dementia, follow-up screening was performed in 1993 and 1994 and again in 1997 through 1999. The risk of Alzheimer's disease was estimated in relation to the use of NSAIDs as documented in pharmacy records. We defined four mutually exclusive categories of use: nonuse, short-term use (1 month or less of cumulative use), intermediate-term use (more than 1 but less than 24 months of cumulative use), and long-term use (24 months or more of cumulative use). Adjustments were made by Cox regression analysis for age, sex, education, smoking status, and the use or nonuse of salicylates, histamine Hz-receptor antagonists, antihypertensive agents, and hypoglycemic agents. RESULTS: During an average follow-up period of 6.8 years, dementia developed in 394 subjects, of whom 293 had Alzheimer's disease, 56 vascular dementia, and 45 other types of dementia. The relative risk of Alzheimer's disease was 0.95 (95 percent confidence interval, 0.70 to 1.29) in subjects with short-term use of NSAIDs, 0.83 (95 percent confidence interval, 0.62 to 1.11) in those with intermediate-term use, and 0.20 (95 percent confidence interval, 0.05 to 0.83) in those with long-term use. The risk did not vary according to age. The use of NSAIDs was not associated with a reduction in the risk of vascular dementia. CONCLUSIONS: The long-term use of NSAIDs may protect against Alzheimer's disease but not against vascular dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recognition that a robust inflammatory response contributes to AD also fuelled the discovery that long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) reduced the risk for AD, delayed disease onset, and slowed cognitive decline (McGeer et al., 1996;Stewart et al., 1997;in t' in t'Veld et al., 2001).”
From PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice (2012) · cites this paper as in t'Veld et al., 2001
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Roth, M., Tym, E., Mountjoy, C. Q., Huppert, F. A., Hendrie, H., Verma, S., & Goddard, R. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.149.6.698 · Cited by 2,090
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Determinants of disease and disability in the elderly: The Rotterdam elderly study
Albert Hofman, D., Grobbee, D. E., de Jong, P. T. V. M., & Ouweland, F. A. V. D. (1991) · European Journal of Epidemiology · doi:10.1007/bf00145007 · Cited by 1,120
Research works printed but not linked: 4
- Brooks W, 1998, Neurobiol Aging, 19, S140
- Kukull WA, 1994, Neurology, 44, A237
- Cornelius C, 1998, Neurobiol Aging, 19, S28
- Time-varying explanatory variables. In: Clayton D, Hills M. Statistical models in epidemiology. Oxford, England: Oxford University Press, 1993:307-18.
Cited by
Sorted by citations
Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Inflammatory Blockade Restores Adult Hippocampal Neurogenesis
Monje, M. L., Toda, H., & Palmer, T. D. (2003) · Science · doi:10.1126/science.1088417 · Cited by 2,426
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
How neuroinflammation contributes to neurodegeneration
Ransohoff, R. M. (2016) · Science · doi:10.1126/science.aag2590 · Cited by 1,967
Innate immune activation in neurodegenerative disease
Heneka, M. T., Kummer, M. P., & Latz, E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3705 · Cited by 1,437
The Rotterdam Study: objectives and design update
Albert Hofman, D., Breteler, M. M. B., van Duijn, C. M., Krestin, G. P., Pols, H. A. P., Stricker, B. H. C., Tiemeier, H. W., Uitterlinden, A. G., Vingerling, J. R., & Witteman, J. C. M. (2007) · European Journal of Epidemiology · doi:10.1007/s10654-007-9199-x · Cited by 1,408
Self-citationSimard, A. R., Soulet, D., Gowing, G., Julien, J.-P., & Rivest, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.022 · Cited by 1,265
Wada, K., Tanaka, K., & Nakashima, K. (2011) · PubMed · Cited by 1,132
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Innate immunity in Alzheimer's disease
Heneka, M. T., Golenbock, D. T., & Latz, E. (2015) · Nature Immunology · doi:10.1038/ni.3102 · Cited by 902
Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women The Cache County Study
Zandi, P. P. (2002) · JAMA · doi:10.1001/jama.288.17.2123 · Cited by 908
Microglia-mediated neuroinflammation in neurodegenerative diseases
Subhramanyam, C. S., Wang, C., Hu, Q., & Dheen, S. T. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.004 · Cited by 897
Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin
Zenaro, E., Pietronigro, E., Bianca, V. D., Piacentino, G., Marongiu, L., Budui, S., Turano, E., Rossi, B., Angiari, S., Dusi, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3913 · Cited by 865
A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines
Rubio-Perez, J. M., & Morillas-Ruiz, J. M. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/756357 · Cited by 864
Oxidative stress in brain agingImplications for therapeutics of neurodegenerative diseases
Floyd, R. A., & Hensley, K. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00019-2 · Cited by 837
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics
Selkoe, D. J., & Schenk, D. (2003) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140248 · Cited by 829
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Ginger—An Herbal Medicinal Product with Broad Anti-Inflammatory Actions
Grzanna, R., Lindmark, L., & Frondoza, C. G. (2005) · Journal of Medicinal Food · doi:10.1089/jmf.2005.8.125 · Cited by 817
Inflammatory Proteins in Plasma and the Risk of Dementia: The Rotterdam Study
Engelhart, M. J., Geerlings, M. I., Meijer, J., Kiliaan, A., Ruitenberg, A., van Swieten, J. C., Stijnen, T., Hofman, A., Witteman, J. C. M., & Breteler, M. M. B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.668 · Cited by 10
Self-citationFreund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L.-O., & Palmblad, J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1402 · Cited by 751
The role of inflammation in Alzheimer’s disease
Tuppo, E. E., & Arias, H. R. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.009 · Cited by 734
Treatment of Alzheimer's disease; current status and new perspectives
Scarpini, E. A., Scheltens, P., & Feldman, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00502-7 · Cited by 723
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration
Prinz, M., Priller, J., Sisodia, S. S., & Ransohoff, R. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2923 · Cited by 674
Cytokines and cognition–the case for a head-to-toe inflammatory paradigm.
Wilson, C. J., Finch, C. E., & Cohen, H. J. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50619.x · Cited by 637
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. Á., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 641
Benito, C., Núñez, E., Tolón, R. M., Carrier, E. J., Rábano, A., Hillard, C. J., & Romero, J. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-35-11136.2003 · Cited by 636
“…to note that the use of anti-inflammatory compounds is currently one of the most promising lines of research for the treatment of AD; thus, the beneficial effects of cyclooxygenase inhibitors (such as ibuprofen or aspirin) have recently been reported (In'T Veld et al., 2001; Zandi et al., 2002).”
BackgroundNSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634
Age-related inflammatory cytokines and disease
Brüünsgaard, H., & Pedersen, B. K. (2003) · Immunology and Allergy Clinics of North America · doi:10.1016/s0889-8561(02)00056-5 · Cited by 608
“Long-term treatment with nonsteroidal anti-inflammatory drugs protects against the disease [97], although it has not been resolved how and when inflammation arises.”
BackgroundInvolvement of oxidative stress in Alzheimer disease
Nunomura, A., Castellani, R. J., Zhu, X., Moreira, P. I., Perry, G., & Smith, M. A. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000228136.58062.bf · Cited by 611
Shimizu, T. (2008) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145616 · Cited by 593
The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective
Shaftel, S. S., Griffin, W. S. T., & O'Banion, M. K. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-7 · Cited by 565
Protective effects of NSAIDs on the development of Alzheimer disease
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008) · Neurology · doi:10.1212/01.wnl.0000311269.57716.63 · Cited by 535
Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits
Min, S.-W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., Shirakawa, K., Minami, S. S., Defensor, E., Mok, S. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3951 · Cited by 516
Inflammation and the Degenerative Diseases of Aging
McGeer, P. L., & McGeer, E. G. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.007 · Cited by 530
E PIDEMIOLOGY OF N EURODEGENERATION
Mayeux, R. P. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.043002.094919 · Cited by 531
Etminan, M., Gill, S., & Samii, A. (2003) · BMJ · doi:10.1136/bmj.327.7407.128 · Cited by 511
Heat Shock Response Modulators as Therapeutic Tools for Diseases of Protein Conformation
Westerheide, S. D., & Morimoto, R. I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.r500010200 · Cited by 484
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Kitazawa, M., Cheng, D., Tsukamoto, M. R., Koike, M. A., Wes, P. D., Vasilevko, V., Cribbs, D. H., & LaFerla, F. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100620 · Cited by 473
Inflammatory processes in Alzheimer's disease
McGeer, E. G., & McGeer, P. L. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00124-6 · Cited by 475
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467
The microglial "activation" continuum: from innate to adaptive responses
Town, T., Nikolic, V., & Tan, J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-24 · Cited by 467
“Furthermore, there is a large body of evidence that non-steroidal anti-inflammatory drug (NSAID) use is associated with reduced risk for AD in humans [ 64-66 ], (for a review see [67]), and NSAID treatment of AD mice results in reduced amyloid plaque burden concomitant with ameliorated microglial activation [68-70].”
Innate immunity and inflammation in ageing: a key for understanding age-related diseases
Licastro, F., Candore, G., Lio, D., Porcellini, E., Colonna-Romano, G., Franceschi, C., & Caruso, C. (2005) · Immunity & Ageing · doi:10.1186/1742-4933-2-8 · Cited by 453
Koenigsknecht-Talboo, J., & Landreth, G. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1808-05.2005 · Cited by 477
Dietary factors and Alzheimer's disease
Luchsinger, J. A., & Mayeux, R. P. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00878-6 · Cited by 442
Neuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433
Visualising microglial activation in vivo
Banati, R. B. (2002) · Glia · doi:10.1002/glia.10144 · Cited by 428
“Some epidemiological studies have found a protective effect of antiinflammatory medication against the risk of developing late-onset Alzheimer-type dementia (McGeer and McGeer, 1995; in t’ Veld et al., 2001) that lends support to this view.”
BackgroundToll-like receptors in neurodegeneration
Okun, E., Griffioen, K. J. S., Lathia, J. D., Tang, S., Mattson, M. P., & Arumugam, T. V. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.09.001 · Cited by 444
“Neuroinflammation is proposed to play a major role in AD pathogenesis, as long term treatment with non-steroidal antiinflammatory drugs reduces AD risk and may delay disease progression (Stewart et al., 1997; in t' Veld et al., 2001).”
BackgroundThe impact of systemic infection on the progression of neurodegenerative disease
Perry, V. H., Newman, T. A., & Cunningham, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1032 · Cited by 428
Inflammatory process in Alzheimer's Disease
Meraz-Ríos, M. A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hernández, J., & Campos-Peña, V. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00059 · Cited by 427
“The Rotterdam study (In’T Veld et al., 2001), Multi-Institutional Research Alzheimer’s Genetic Epidemiology Study (Yip et al., 2005) and Canadian Study of Health and Aging (CSHA) (Coté et al., 2012) also observed an association between the NSAID use and a reduced AD risk.”
BackgroundContribution of inflammatory processes to Alzheimer's disease: molecular mechanisms
Sastre, M., Klockgether, T., & Heneka, M. T. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.014 · Cited by 426
“Epidemiological studies have documented a beneficial effect of non-steroideal anti-inflammatory drugs (NSAIDs) in AD (Rogers et al., 1993; McGeer et al., 1996; Stewart et al., 1997; Akiyama et al., 2000; In’t Veld et al., 2001; Szekely et al., 2004).”
BackgroundInfluentialThe contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease
Minter, M. R., Taylor, J. M., & Crack, P. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13411 · Cited by 451
“Epidemiological evidence suggests that treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), prior to disease onset, can delay AD (in t’ Veld et al. 2001).”
BackgroundClinical manifestations of cerebral amyloid angiopathy–related inflammation
Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W., & Greenberg, S. M. (2004) · Annals of Neurology · doi:10.1002/ana.10810 · Cited by 417
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498
Neuroinflammation in Alzheimer's disease and prion disease
Eikelenboom, P., Bate, C., van Gool, W. A., Hoozemans, J. J. M., Rozemüller, A. J. M., Veerhuis, R., & Williams, A. (2002) · Glia · doi:10.1002/glia.10146 · Cited by 412
“The idea that the neuroinflammatory response is an interesting therapeutic target for treatment with antiinflammatory drugs was also strongly supported by epidemiological studies showing that the use of classical NSAIDS can prevent or retard AD (McGeer et al., 1996; in t’ Veld et al., 2001).”
BackgroundA Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
McGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400
Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review
Szekely, C. A., Thorne, J. E., Zandi, P. P., Ek, M., Messias, E., Breitner, J. C. S., & Goodman, S. N. (2004) · Neuroepidemiology · doi:10.1159/000078501 · Cited by 402
Apolipoprotein E in Alzheimer's Disease: An Update
Yu, J.-T., Tan, L., & Hardy, J. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014300 · Cited by 394
“Additionally, several epidemiological and prospective studies suggest that long-term use of NSAIDs was associated with a significantly lower risk of AD in APOE ε4 subjects (in ‘t Veld et al. 2001, Szekely et al. 2008).”
BackgroundReines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R., Norman, B., & Baranak, C. C. (2004) · Neurology · doi:10.1212/wnl.62.1.66 · Cited by 384
Nonsteroidal Anti-inflammatory Drugs in Ophthalmology
Kim, S. J., Flach, A. J., & Jampol, L. M. (2010) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.07.005 · Cited by 388
Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies
Selkoe, D. J. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-8-200404200-00047 · Cited by 208
Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., & Landreth, G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07504.2003 · Cited by 469
“The observation that chronic NSAID treatment could diminish AD risk (Stewart et al., 1997; in t’ Veld et al., 2001) and alter A plaque pathology in transgenic mice (Lim et al., 2000) led us to examine in greater detail the regulation of A metabolism and deposition by this class of drugs.”
BackgroundThe Rotterdam Study: 2016 objectives and design update
Albert Hofman, D., Brusselle, G., Murad, S. D., van Duijn, C. M., Franco, O. H., Goedegebure, A., Ikram, M. A., Klaver, C. C. W., Nijsten, T. E. C., Peeters, R. P., et al. (2015) · European Journal of Epidemiology · doi:10.1007/s10654-015-0082-x · Cited by 385
Self-citationBlasko, I., Stampfer‐Kountchev, M., Robatscher, P., Veerhuis, R., Eikelenboom, P., & Grubeck‐Loebenstein, B. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00101.x · Cited by 374
Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., Evert, B. O., Dumitrescu-Ozimek, L., Thal, D. R., Landreth, G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503839103 · Cited by 373
Hampel, H. J., Mesulam, M. M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.43 · Cited by 374
“For example, pharmacoepidemiology data suggest that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) may protect against AD (74, 75); and at preclinical stages, NSAIDs may diminish significantly AD prevalence (42), while they are ineffective after its clinical presentation (43).”
Gorelick, P. B. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05726.x · Cited by 361
Risk Factors for Vascular Dementia and Alzheimer Disease
Gorelick, P. B. (2004) · Stroke · doi:10.1161/01.str.0000143318.70292.47 · Cited by 365
Montgomery, S. L., & Bowers, W. J. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9287-2 · Cited by 372
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
Sastre, M., Dewachter, I., Landreth, G. E., Willson, T. M., Klockgether, T., LEUVEN, F. V., & Heneka, M. T. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-30-09796.2003 · Cited by 361
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease
Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & Felice, F. G. D. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.010 · Cited by 363
Vegeto, E., Benedusi, V., & Maggi, A. C. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2008.04.001 · Cited by 364
Naturally occurring phytochemicals for the prevention of Alzheimer’s disease
Kim, J., Lee, H. J., & Lee, K. W. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06562.x · Cited by 361
“NSAIDs appear to exert a protective effect against the development of AD (Breitner et al. 1994; in t’ Veld et al. 2001; Zandi et al.”
BackgroundNeuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease
Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., & Maccioni, R. B. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.10.001 · Cited by 351
Interleukin-6 Covaries Inversely with Hippocampal Grey Matter Volume in Middle-Aged Adults
Marsland, A. L., Gianaros, P. J., Abramowitch, S. M., Manuck, S. B., & Hariri, A. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.016 · Cited by 348
Current Pharmacotherapy for Alzheimer's Disease
Lleó, A., Greenberg, S. M., & Growdon, J. H. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131442 · Cited by 347
Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis
Henstridge, C. M., Hyman, B. T., & Spires-Jones, T. L. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0113-1 · Cited by 348
Role of inflammation in neurodegenerative diseases
Minghetti, L. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000169752.54191.97 · Cited by 335
Ineffective phagocytosis of amyloid-β by macrophages of Alzheimer's disease patients
Fiala, M., Lin, J., Ringman, J. M., Kermani-Arab, V., Tsao, G., Patel, A. J., Lossinsky, A. S., Graves, M. C., Gustavson, A. R., Sayre, J. W., et al. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-7304 · Cited by 331
The Rotterdam Study: 2014 objectives and design update
Albert Hofman, D., Murad, S. D., van Duijn, C. M., Franco, O. H., Goedegebure, A., Ikram, M. A., Klaver, C. C. W., Nijsten, T. E. C., Peeters, R. P., Stricker, B. H. C., et al. (2013) · European Journal of Epidemiology · doi:10.1007/s10654-013-9866-z · Cited by 335
Self-citationExtended results of the Alzheimer's disease anti‐inflammatory prevention trial
Breitner, J. C. S., Baker, L. D., Montine, T. J., Meinert, C. L., Lyketsos, C. G., Ashe, K. H., Brandt, J., Craft, S., Evans, D. A., Green, R. C., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.014 · Cited by 327
Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease
Holmes, C. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.6.788 · Cited by 330
Alzheimer's Disease and Mild Cognitive Impairment
Kelley, B. J., & Petersen, R. C. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.008 · Cited by 335
Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M. P., & Heneka, M. T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1569-12.2012 · Cited by 326
Inflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
HENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317
Reduced incidence of AD with NSAID but not H2receptor antagonists
Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K. M., Mayer, L. S., & Breitner, J. C. S. (2002) · Neurology · doi:10.1212/wnl.59.6.880 · Cited by 317
Neurotoxic Effects of Aluminium Among Foundry Workers and Alzheimer’s Disease
Polizzi, S., Pira, E., Ferrara, M., Bugiani, M., Papaleo, A., Albera, R., & Palmi, S. (2002) · NeuroToxicology · doi:10.1016/s0161-813x(02)00097-9 · Cited by 319
Hensley, K., Benaksas, E. J., Bolli, R., Comp, P. C., Grammas, P., Hamdheydari, L., Mou, S., Pye, Q. N., Stoddard, M. F., Wallis, G., et al. (2003) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.10.009 · Cited by 313
The LPS receptor (CD14) links innate immunity with Alzheimer's disease
Fassbender, K., Walter, S., Kühl, S., Landmann, R., Ishii, K., Bertsch, T., Stalder, A. K., Muehlhauser, F., Liu, Y., Ulmer, A. J., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0364fje · Cited by 307
Jaturapatporn, D., Isaac, M. G. E. K. N., McCleery, J. M., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006378.pub2 · Cited by 311
Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293
Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Li, C., Zhao, R., Gao, K., Wei, Z. Z., Yin, M. Y., Lau, L. T., Chui, D., & Yu, A. C. (2011) · Current Alzheimer Research · doi:10.2174/156720511794604543 · Cited by 294
Metadata
- Authors
- in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C.
- Affiliations
- Erasmus MC (NL)
- National Institutes of Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-11-22
- Volume
- 345
- Issue
- 21
- Pages
- 1515-1521
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2083556882
- Semantic Scholar
- 29c01ac52ec50618ec7b3b87ca55b707ca397434
- Cited by
- 1,196
- References
- 44
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 18 · 2023: 23 · 2022: 26 · 2021: 33 · 2020: 23 · 2019: 40 · 2018: 38 · 2017: 28 · 2016: 40 · 2015: 49 · 2014: 49 · 2013: 39 · 2012: 50
- FWCI
- 52.61
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- nonsteroidal anti-inflammatory drugs, Alzheimer's disease, vascular dementia, dementia risk, long-term NSAID use, older adults
- MeSH terms
- Aged, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Prospective Studies, Risk, Salicylates, Dementia, Vascular, Cohort Studies, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
